Mobile application-based Bristol stool scale for Hepatic Coma

Phase-Based Progress Estimates
Mayo Clinic Rochester, Rochester, MN
Hepatic Coma+1 More
Dieta mobile application - Other
All Sexes
What conditions do you have?

Study Summary

This study is being done to assess the safety and efficacy of using mobile application-based Bristol stool scale to titrate lactulose in prevention episodes of hepatic encephalopathy.

Eligible Conditions

  • Hepatic Coma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 4 weeks

4 weeks
Achievement of daily stool goal

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Mobile application-based Bristol stool scale
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Mobile application-based Bristol stool scale · No Placebo Group · N/A

Mobile application-based Bristol stool scale
Experimental Group · 1 Intervention: Dieta mobile application · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 weeks

Trial Background

Douglas (Doug) A. Simonetto, Principal Investigator
Principal Investigator
Mayo Clinic
Closest Location: Mayo Clinic Rochester · Rochester, MN
Photo of Mayo Clinic Rochester  1Photo of Mayo Clinic Rochester  2Photo of Mayo Clinic Rochester  3
2005First Recorded Clinical Trial
0 TrialsResearching Hepatic Coma
156 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are taking lactulose daily for prevention of hepatic encephalopathy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.